Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study
Main finding · At least one endocrine or metabolic diseaseResult — go to the resultPrevalence ratio 1.9 95% CI 1.8–2.0Authors' conclusion
Our study highlights the increased vulnerability of CCS to endocrine and metabolic diseases compared to the general population and underscores the need for risk-adapted surveillance during the whole survivorship trajectory.
Study context
- Population
- Five-year childhood cancer survivors (CCS) from the nationwide German Childhood Cancer Registry and a matched comparison population; insurance period 2017–2021matched cohort
- Participants
- 11,863 vs 35,589
- Exposure
- Five-year childhood cancer survivors vs matched comparison group without childhood cancer
- CCSn = 11,863
- Comparisonn = 35,589reference
- Outcome
- Prevalence of at least one endocrine or metabolic disease
- Follow-up
- 2017-2021
Methodological detailsrecord linkage of German Childhood Cancer Registry and claims data from 13 statutory health insurances, matched comparison group
- Record linkage of German Childhood Cancer Registry and claims data from 13 statutory health insurances
- Matched comparison group
Main finding
At least one endocrine or metabolic disease
Prevalence ratio
1.9
95% CI 1.8–2.0
Events by group
CCSvs Comparison
PR 1.9 (95% CI 1.8–2.0)
As reported in the abstract
Observational data: associations, not effects.
Further findings
≥1 endocrine or metabolic disease, males
- PR for males
- 2.4 (95% CI: 2.3-2.5)
≥1 endocrine or metabolic disease, females
- PR for females
- 1.6 (95% CI: 1.5-1.7)
- Frequency of diseases higher among females than males in both groups
≥1 disease by attained age
- Frequency of ≥1 disease increased with increasing attained age
Hypothyroidism among CCS
- Disease with highest frequency among CCS: hypothyroidism
- 15.85%
Highest PR: patients with primary thyroid cancer
- PR for patients with primary thyroid cancer
- 43.5 (95% CI: 24.2-78.1)
Original publication
Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study. Eur J Endocrinol. Published 19 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →